Investment Stage – Series A & B
Carrick Therapeutics is building an innovative portfolio of first-in-class cancer treatments that target multiple mechanisms of the most aggressive forms.
Carrick Therapeutics Website
Spex Capital Ltd is an appointed representative of J8 Capital Management LLP which is authorised and regulated by the Financial Conduct Authority.
©2022 · Spex Capital
©2021 · Spex Capital